Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Eltrombopag Combined with Cyclosporine As First-Line Therapy in Adults with Severe Acquired Aplastic Anemia: Results of the Interventional Phase 2 Single-Arm Soar Study

Carlos Vallejo, Jun Ho Jang, Carlo Finelli, Efreen Montaño Figueroa, Lalita Norasetthada, Rodrigo T. Calado, Mehmet Turgut, Regis Peffault De Latour, Ulrike Kriemler-Krahn, Jens Haenig, Joan Maier, Phillip Scheinberg

Blood (2021) 138 (Supplement 1): 2174.

https://doi.org/10.1182/blood-2021-147733

Published: 2021

Journal Articles

Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Non-Invasive Measurement of Liver Iron Concentration

Timothy G St Pierre, PhD, Amal El-Beshlawy, MD, Mohsen Saleh Elalfy, MD, Abdullah Al Jefri, MD, Kusai Al Zir, MD, Shahina Daar, MD, Dany Habr, MD, Ulrike Kriemler-Krahn, Ali Taher, MD

Blood (2010) 116 (21): 2053.

https://doi.org/10.1182/blood.V116.21.2053.2053

Published: 2010

Journal Articles

Efficacy and Safety of Once-Daily Oral Deferasirox (Exjade ® ) during a Median of 2.7 Years of Treatment in Heavily Iron-Overloaded Patients with β-Thalassemia

Ali Taher, Amal El-Beshlawy, Mohsen Saleh Elalfy, Kusai Al Zir, Shahina Daar, Ghazi Damanhouri, Dany Habr, Ulrike Kriemler-Krahn, Abdel Hmissi, Abdullah Al Jefri

Blood (2008) 112 (11): 5409.

https://doi.org/10.1182/blood.V112.11.5409.5409

Published: 2008

Journal Articles

Efficacy and Safety of Deferasirox (Exjade ® ) in Preventing Cardiac Iron Overload in β-Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial

Dudley Pennell, Pranee Sutcharitchan, Amal El-Beshlawy, Yesim Aydinok, Ali Taher, Gillian Smith, Dany Habr, Ulrike Kriemler-Krahn, Abdel Hmissi, John B Porter

Blood (2008) 112 (11): 3874.

https://doi.org/10.1182/blood.V112.11.3874.3874

Published: 2008

Journal Articles

Deferasirox (Exjade ® ) Treatment in Pediatric β-Thalassemia Patients with High Iron Burden: 2.8 Years Results from ESCALATOR Trial

Ali Taher, Abdullah Al Jefri, Mohsen Saleh Elalfy, Kusai Al Zir, Shahina Daar, Ghazi Damanhouri, Ulrike Kriemler-Krahn, Dany Habr, Abdel Hmissi, Amal El-Beshlawy

Blood (2008) 112 (11): 3879.

https://doi.org/10.1182/blood.V112.11.3879.3879

Published: 2008

Journal Articles

Oral Deferasirox (Exjade®, ICL670) Is Effective, with a Clinically Manageable Safety Profile, in Pediatric β-Thalassemia Patients with High Iron Burden.

Ali Taher, Abdullah Al Jefri, Mohsen Saleh Elalfy, Kusai Al Zir, Shahina Daar, Ghazi Damanhouri, Ulrike Kriemler-Krahn, Dietrich Pfluger, Dominik Hadler, Amal El-Beshlawy

Blood (2007) 110 (11): 2779.

https://doi.org/10.1182/blood.V110.11.2779.2779

Published: 2007

NARROW

Efficacy and Safety of Eltrombopag Combined with Cyclosporine As First-Line Therapy in Adults with Severe Acquired Aplastic Anemia: Results of the Interventional Phase 2 Single-Arm Soar Study

Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Non-Invasive Measurement of Liver Iron Concentration

Efficacy and Safety of Once-Daily Oral Deferasirox (Exjade ® ) during a Median of 2.7 Years of Treatment in Heavily Iron-Overloaded Patients with β-Thalassemia

Efficacy and Safety of Deferasirox (Exjade ® ) in Preventing Cardiac Iron Overload in β-Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial

Deferasirox (Exjade ® ) Treatment in Pediatric β-Thalassemia Patients with High Iron Burden: 2.8 Years Results from ESCALATOR Trial

Oral Deferasirox (Exjade®, ICL670) Is Effective, with a Clinically Manageable Safety Profile, in Pediatric β-Thalassemia Patients with High Iron Burden.

Email alerts

ASH Publications

American Society of Hematology

Efficacy and Safety of Eltrombopag Combined with Cyclosporine As First-Line Therapy in Adults with Severe Acquired Aplastic Anemia: Results of the Interventional Phase 2 Single-Arm Soar Study

Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Non-Invasive Measurement of Liver Iron Concentration

Efficacy and Safety of Once-Daily Oral Deferasirox (Exjade ® ) during a Median of 2.7 Years of Treatment in Heavily Iron-Overloaded Patients with β-Thalassemia

Efficacy and Safety of Deferasirox (Exjade ® ) in Preventing Cardiac Iron Overload in β-Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial

Deferasirox (Exjade ® ) Treatment in Pediatric β-Thalassemia Patients with High Iron Burden: 2.8 Years Results from ESCALATOR Trial

Oral Deferasirox (Exjade®, ICL670) Is Effective, with a Clinically Manageable Safety Profile, in Pediatric β-Thalassemia Patients with High Iron Burden.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only